Secondary cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma

Gynecologic Oncology

Volumn 83, Issue 3, 2001, Pages 504-512

  Scarabelli, Carlo ^a   Gallo, Angelo ^a   Carbone, Antonino ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Cytoreduction; Ovarian cancer; Recurrence; Surgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; SECOND LOOK SURGERY;

EID: 0035209811     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6404     Document Type: Article

References (32)

1. Surgery during chemotherapy and at relapse of ovarian cancer
2. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer
3. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response
4. Secondary cytoreduction for ovarian cancer following cisplatin therapy
5. Secondary cytoreductive for recurrent ovarian cancer. A prospective study
6. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma
7. Secondary cytoreductive surgery in epithelial ovarian cancer: Non responders to first-line therapy
8. Secondary cytoreductive surgery in ovarian cancer
9. Second-look laparotomy in epithelial ovarian carcinoma
10. Feasibility and outcome of complete secondary tumor resection for patients with advanced ovarian cancer
11. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma
12. Survival of patients following secondary cytoreductive surgery in ovarian cancer
13. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: Influence of a prior response to intravenous cisplatin
14. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum based regimens
15. Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: A phase II study
16. Topotecan in platinum- and paclitaxel-resistant ovarian cancer
17. Systematic pelvic and para-aortic lymphadenectomy in advanced ovarian cancer patients with no residual intraperitoneal disease
18. Splenectomy during primary and secondary cytoreductive surgery for epithelial ovarian carcinoma
19. Non parametric estimation from incomplete observations
20. Evaluation of survival data and two new rank order statistics arising in its consideration
21. Regression models and life tables
22. Secondary surgical cytoreduction for advanced epithelial ovarian cancer
23. Secondary cytoreduction in epithelial ovarian cancer
24. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer
25. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma
26. Modified posterior exenteration for ovarian cancer
27. "Second effort" surgical resection for bulky ovarian cancer
28. Paclitaxel for platinum-refractory ovarian cancer: Results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103
29. High-dose intensity regimens with epirubicin in ovarian cancer
30. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: Results of a large European phase II study
31. Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group study
32. Systematic pelvic and para-aortic lymphadenectomy during cytoreductive surgery in advanced ovarian cancer: Potential benefit on survival